All In Biotech

NDA 214154 · Mayne Pharma

Nextstellis

Drospirenone, Estetrol · Oral

Novel

CDER novel approval, Apr 15, 2021: To prevent pregnancy

Last checked: Nov 20, 2026Latest source record: Apr 29, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Apr 15, 2021

Approved uses

1

Original approval plus efficacy supplements

Registered trials

146

48 Phase 3, 7 recruiting

FAERS reports

296

102 serious, 3 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combined hormonal contraceptive (CHC) use. This risk increases with age, particularly in females over 35 years of age, and with the number of cigarettes smoked. For this reason, CHCs, including NEXTSTELLIS, are contraindicated in females who are over 35 years of age and smoke. [See Contraindications (4) and Warnings and Precautions (5.1) ] WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS See full prescribing information for complete boxed warning . Females over 35 years old who smoke should not use NEXTSTELLIS ( 4 ) Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. ( 4 )

What it is approved for

From the label in effect May 11, 2023.

NEXTSTELLIS is indicated for use by females of reproductive potential to prevent pregnancy. NEXTSTELLIS is a combination of drospirenone, a progestin, and estetrol, an estrogen, indicated for use by females of reproductive potential to prevent pregnancy. ( 1 ) Limitations of Use NEXTSTELLIS may be less effective in females with a BMI ≥ 30 kg/m 2 . In females with BMI ≥ 30 kg/m 2 , decreasing effectiveness may be associated with increasing BMI ( 14 ). Limitations of Use NEXTSTELLIS may be less effective in females with a BMI ≥ 30 kg/m 2 . In females with BMI ≥ 30 kg/m 2 , decreasing effectiveness may be associated with increasing BMI [see Clinical Studies (14) ].

Mechanism: CHCs prevent pregnancy primarily by suppressing ovulation.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 15, 2021 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination NovelLabelLetterReview
1 products under this application
  • NEXTSTELLIS · DROSPIRENONE 3MG; ESTETROL 14.2MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Drospirenone" as an intervention, any sponsor and status, largest first.

All 146 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • intermenstrual bleeding26
  • heavy menstrual bleeding21
  • headache16
  • drug ineffective15
  • dizziness13
  • mood swings12
  • off label use12
  • nausea11
  • product use in unapproved indication11
  • migraine10
  • suicidal ideation10
  • weight increased10

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20217
202275
202364
202428
202545
202677

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Nextstellis (Drospirenone/Estetrol)

2024 spending

$94K

Beneficiaries

81

267 claims

Per beneficiary

$1,159

$7.20 per unit

View as table
YearSpending
2020$0
2021$6,196
2022$36,668
2023$78,373
2024$93,910

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 311 on PubMed

Sponsor: Mayne Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.